IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO

Abstract

Introduction: The ibrutinib‐rituximab combination produced durable responses in 88% of relapsed/refractory mantle cell lymphoma (MCL) patients, providing a "Window" of opportunity to use chemotherapyfree induction with ibrutinib‐rituximab followed by fewer cycles of chemo‐immunotherapy in young, fit patients with newly diagnosed MCL. Methods: Enrollment began in June 2015 for a Phase II single‐center clinical trial consisting of a chemotherapy‐free phase of ibrutinib‐rituximab treatment (Part 1) until best response, followed by a shortened intense chemo‐immunotherapy course (Part 2) among newly diagnosed MCL patients of